The current analysis might have the following advantages: (i) this study is the first systematical meta-analysis regarding association between rs78378222 and overall cancer risk; (ii) rs78378222 is a newly reported rare variant on TP53 in recent years and the included data was mostly from GWAS and high-throughput sequencing, which was more credible; (iii) the sample size is very large (127,871) and the subjects are mostly selected from multi-center cancer registry community. This evidence concerns the gene TP53 and cancer.